Search
Showing results for "clinical trials"
Malignant central nervous system (CNS) cancers are among the most difficult to treat, with low rates of survival and a high likelihood of recurrence. This is primarily due to their location within the CNS, hindering adequate drug delivery and tumour access via surgery. Furthermore, CNS cancer cells are highly plastic, an adaptive property that enables them to bypass targeted treatment strategies and develop drug resistance.
Both tumour suppressive and oncogenic functions have been reported for dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). Herein, we performed a detailed investigation to delineate the role of DYRK1A in glioblastoma. Our phosphoproteomic and mechanistic studies show that DYRK1A induces degradation of cyclin B by phosphorylating CDC23, which is necessary for the function of the anaphase-promoting complex, a ubiquitin ligase that degrades mitotic proteins.
These findings reveal a central role of the DG receptor, not only as a structural element, but also as a critical factor promoting mesenchymal-like GBM
In this review, we describe both the mechanisms and the therapeutic evidence from preclinical and clinical studies exploring the role of prebiotics in allergy prevention
Our findings present a novel mouse model for glioma demonstrating that the PI3K pathway is important for initiation of tumorigenesis
Early changes in cell morphology upon treatments are a strong indication that the inhibitor is directly targeting tubulin
These findings implicate the activation of STAT3 as one pathway that may mediate resistance to IGF-II-targeted therapy in HCC
The Wesfarmers Centre is pleased to announce the successful recipients for the 2018 Round 2 Seed Funding Grants. The Wesfarmers Centre Scientific
Staphylococcus aureus bacteremia (SAB) is the most common cause of childhood sepsis contributing to pediatric intensive care unit admission. The cost of adult SAB hospitalization is well described globally, but limited costing information is available for children. To bridge this knowledge gap, we investigated the cost of hospitalization in children with SAB in Australia.
Two international trials led by The Kids Research Institute Australia’s Neonatal and Infection Immunity Team are tackling the urgent need for simple and safe interventions that can help prevent the adverse long-term effects of infections in extremely preterm babies.